David A. Siegel Tyme Technologies, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.23 - $0.35 $32,016 - $48,720	-139,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $36,092 - $87,652	128,900 Added 1251.46%	139,200 $49,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.04 $3,840 - $6,656	-6,400 Reduced 38.32%	10,300 $6,000
Q3 2021 Nov 15, 2021	BUY	$0.99 - $1.38 $4,356 - $6,071	4,400 Added 35.77%	16,700 $17,000
Q2 2021 Aug 16, 2021	BUY	$1.14 - $1.87 $14,021 - $23,001	12,300 New	12,300 $15,000
Q4 2020 Feb 16, 2021	SELL	$0.87 - $1.26 $33,321 - $48,258	-38,300 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$0.93 - $1.35 $25,203 - $36,585	27,100 Added 241.96%	38,300 $38,000
Q2 2020 Aug 14, 2020	BUY	$0.97 - $1.7 $10,864 - $19,040	11,200 New	11,200 $15,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.